An integrated, quality by design (QbD) approach for design, development and optimization of orally disintegrating tablet formulation of carbamazepine

Abstract

The objective of the present study was to design and develop a formulation for orally disintegrating tablets (ODTs) of carbamazepine using quality by design principles. The target product profile (TPP) and quality target product profile (QTPP) of ODTs were identified. Risk assessment was carried out by leveraging prior knowledge and experience to define the criticality of factors based on their impact by Ishikawa fishbone diagram and preliminary hazard analysis tool. Box–Behnken response surface methodology was used to study the effect of critical factors on various attributes of ODTs. The independent factors selected were compression pressure (X₁), concentration of sublimating agent (volatile material) (X₂), disintegrant concentration (X₃) and the responses were tablet crushing strength, tablet porosity, disintegration time, water absorption time, tablet friability and drug dissolution. ANOVA and lack of fit test illustrated that selected independent variables had significant effect on the response variables, and excellent correlation was observed between actual and predicted values. Optimization by desirability function indicated that compression pressure, X₁ (1534 lbs), ammonium bicarbonate concentration, X₂ (7.68%) and Kollidon^® CL-SF concentration, X₃ (6%) were optimum to prepare ODT formulation of carbamazepine of desired attributes complying with QTPP. Thus, in the present study, a high level of assurance was established for ODT product quality and performance.

Keywords:

• Box–Behnken response surface methodology
• ODTs
• optimization
• QbD
• quality target product profile
• risk assessment

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.